|
102 Companies |
|
136 Products |
|
136 Products |
|
123 Mechanisms of Action |
|
5 Trials |
|
1111 News |
|
| «12345678910111213...1617» |
- ||| rivaroxaban / Generic mfg.
Trial completion: Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=131, Completed, Sponsor: Bayer
Active, not recruiting --> Completed
- chloroquine phosphate / Generic mfg., primaquine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=50, Recruiting, Sponsor: Menzies School of Health Research
Active, not recruiting --> Completed Trial primary completion date: Jan 2014 --> May 2015
- ||||| lurasidone / Generic mfg.
Enrollment closed, Trial primary completion date: Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex (clinicaltrials.gov) - Feb 19, 2015
P3, N=1060, Active, not recruiting, Sponsor: Sunovion
Trial primary completion date: Jan 2014 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Apr 2015
- | Enrollment closed, Enrollment change: Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers (clinicaltrials.gov) - Feb 12, 2015
P2, N=31, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting | N=85 --> 31
- Enrollment change: A Prospective Randomized Study Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage (clinicaltrials.gov) - Feb 11, 2015
P=N/A, N=220, Recruiting, Sponsor: Kantonsspital Aarau
Recruiting --> Active, not recruiting | N=85 --> 31 N=300 --> 220
- Trial primary completion date: PRET: Patients Prone to Recurrence After Endovascular Treatment (clinicaltrials.gov) - Feb 10, 2015
P4, N=500, Active, not recruiting, Sponsor: Centre hospitalier de l'Universit
N=300 --> 220 Trial primary completion date: Feb 2015 --> Dec 2015
- | isotretinoin / Generic mfg.
Trial completion: Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin (clinicaltrials.gov) - Feb 10, 2015
P4, N=20, Completed, Sponsor: Dermatrials Research
Trial primary completion date: Feb 2015 --> Dec 2015 Active, not recruiting --> Completed
- ||||| Enrollment closed: Lamotrigine Phase III Study in Bipolar I Disorder (clinicaltrials.gov) - Feb 9, 2015
P3, N=250, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial primary completion date: A Pilot Study Using Weightloss and Exercise to Prevent Recurring Gestational Diabetes in Obese Women (clinicaltrials.gov) - Feb 6, 2015
P=N/A, N=60, Enrolling by invitation, Sponsor: California Polytechnic State University-San Luis Obispo
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2012 --> Sep 2015
- |||| ribavirin / Generic mfg.
Trial completion, Enrollment change, Pre-transplantation, Post-transplantation: Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant (clinicaltrials.gov) - Feb 6, 2015
P2, N=61, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2012 --> Sep 2015 Active, not recruiting --> Completed | N=50 --> 61
- anastrozole / Generic mfg.
Trial primary completion date: Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Feb 5, 2015
P4, N=70, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Active, not recruiting --> Completed | N=50 --> 61 Trial primary completion date: Dec 2013 --> Jul 2015
- Trial primary completion date: Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=402, Active, not recruiting, Sponsor: Centre for the AIDS Programme of Research in South Africa
Trial primary completion date: Dec 2013 --> Jul 2015 Trial primary completion date: May 2013 --> May 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence (clinicaltrials.gov) - Feb 5, 2015
P1, N=24, Recruiting, Sponsor: Brain & Spine Surgeons of New York
Trial primary completion date: May 2013 --> May 2016 Trial primary completion date: Oct 2012 --> Oct 2017
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=30, Completed, Sponsor: National Taiwan University Hospital
Trial primary completion date: Oct 2012 --> Oct 2017 Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jan 2015
- ||| dabigatran etexilate / Generic mfg.
Trial completion: Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=141, Completed, Sponsor: Odense University Hospital
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jan 2015 Recruiting --> Completed
- || Trial primary completion date: THORN: Ability of Home Monitoring (clinicaltrials.gov) - Jan 29, 2015
P=N/A, N=1750, Active, not recruiting, Sponsor: Biotronik SE & Co. KG
Recruiting --> Completed Trial primary completion date: Jun 2013 --> Sep 2013
- Trial initiation date, Trial primary completion date, Tumor cell: Circulating Tumor Cells in Operative Blood (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: University of Florida
Trial primary completion date: Jun 2013 --> Sep 2013 Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: Jul 2015 --> Jan 2016
- Phase classification, Surgery: Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery (clinicaltrials.gov) - Jan 26, 2015
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: Jul 2015 --> Jan 2016 Phase classification: P=N/A --> P1
- || New P3 trial, Head-to-Head: OTV_PRE_01: Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence (clinicaltrials.gov) - Jan 26, 2015
P3, N=296, Recruiting, Sponsor: University Hospital Tuebingen
- | Flynpovi (eflornithine/sulindac) / Panbela Therap
Enrollment change, IO biomarker: Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps (clinicaltrials.gov) - Jan 22, 2015
P3, N=375, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P1 N=150 --> 375
- Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study (clinicaltrials.gov) - Jan 20, 2015
P2/3, N=36, Completed, Sponsor: University of Science Malaysia
- morphine sulphate / Generic mfg.
Enrollment open, Surgery, Minimal residual disease: Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery (clinicaltrials.gov) - Jan 20, 2015
P4, N=60, Recruiting, Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
N=150 --> 375 Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Phase classification, Enrollment change: Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) - Jan 18, 2015
P3, N=60, Recruiting, Sponsor: George W. Burke
Not yet recruiting --> Recruiting Phase classification: P2/3 --> P3 | N=40 --> 60
- Trial primary completion date: DETECT: The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease (clinicaltrials.gov) - Jan 15, 2015
P4, N=136, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase classification: P2/3 --> P3 | N=40 --> 60 Trial primary completion date: Jan 2016 --> Jun 2016
- ||| Biomarker, Enrollment open: The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=3100, Recruiting, Sponsor: Yonsei University
Trial primary completion date: Jan 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- ||| Enrollment open: Clinical Benefits of Additional Complex Fractionated Atrial Electrogram Targeted Catheter Ablation for Longstanding Persistent Atrial Fibrillation (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=220, Recruiting, Sponsor: Yonsei University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Trial completion, Metastases: Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients. (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=200, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| sorafenib / Generic mfg.
Trial completion: Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) (clinicaltrials.gov) - Jan 6, 2015
P3, N=1114, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence (clinicaltrials.gov) - Dec 21, 2014
P=N/A, N=100, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| EXC 001 / Pfizer
Trial completion, Surgery: Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery (clinicaltrials.gov) - Dec 17, 2014
P2, N=100, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Trial completion, Trial primary completion date: Karydakis Procedure Versus Excision With Healing by Secondary Intention (EHSI) in Sacrococcygeal Pilonidal Sinus (clinicaltrials.gov) - Dec 17, 2014
P4, N=321, Completed, Sponsor: Tehran University of Medical Sciences
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2011 --> Mar 2014
- Enrollment closed, Trial primary completion date: Optimizing Postpartum Contraception in Women With Preterm Births (clinicaltrials.gov) - Dec 12, 2014
P=N/A, N=362, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Completed | Trial primary completion date: Sep 2011 --> Mar 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Oct 2014
- Trial completion: Should Colorectal Cancer Patients be Followed After Five Years? Study of Recurrence in a Population Cohort (clinicaltrials.gov) - Dec 12, 2014
P=N/A, N=598, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Oct 2014 Withdrawn --> Completed
- | morphine sulphate / Generic mfg.
New P4 trial, Surgery, Minimal residual disease: Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery (clinicaltrials.gov) - Dec 11, 2014
P4, N=60, Not yet recruiting, Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
- Trial primary completion date: Mucosal Versus Fecal Microbiota in FMT (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=20, Recruiting, Sponsor: Emory University
Withdrawn --> Completed Trial primary completion date: Apr 2015 --> Jul 2015
- Lucentis (ranibizumab) / Roche, Novartis
Clinical: Ranibizumab in Patients With Branch Retinal Vein Occlusion (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=60, Recruiting, Sponsor: Dr. SamiUllah
- Clinical: Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=320, Not yet recruiting, Sponsor: West China Hospital
- cisplatin / Generic mfg., etoposide IV / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Preoperative Treatment of Patients With High Risk Thymoma (clinicaltrials.gov) - Dec 10, 2014
P2, N=21, Completed, Sponsor: Valley Health System
Trial primary completion date: Apr 2015 --> Jul 2015 Active, not recruiting --> Completed | N=30 --> 21 | Trial primary completion date: Oct 2016 --> Oct 2014
- Biomarker, Trial primary completion date: ProFaCo: Prognostic Factors for All Types of Cancer Combined (clinicaltrials.gov) - Dec 7, 2014
P=N/A, N=520, Active, not recruiting, Sponsor: Atrium Medical Center
Active, not recruiting --> Completed | N=30 --> 21 | Trial primary completion date: Oct 2016 --> Oct 2014 Trial primary completion date: Oct 2011 --> Jun 2015
- Trial primary completion date: Should Prosthetic Repair of Incisional Abdominal Hernias be Drain or Not? (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=380, Recruiting, Sponsor: University of Lausanne Hospitals
Trial primary completion date: Oct 2011 --> Jun 2015 Trial primary completion date: Dec 2012 --> Dec 2015
- ||| valacyclovir / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=103, Completed, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Dec 2012 --> Dec 2015 Active, not recruiting --> Completed | N=134 --> 103 | Trial primary completion date: Dec 2013 --> Apr 2014
- Trial primary completion date: Mesalazine Effects in Sporadic Colorectal Adenoma Patients (clinicaltrials.gov) - Dec 5, 2014
P2, N=68, Recruiting, Sponsor: UMC Utrecht
Active, not recruiting --> Completed | N=134 --> 103 | Trial primary completion date: Dec 2013 --> Apr 2014 Trial primary completion date: Dec 2014 --> Jun 2015
- Trial primary completion date: ENERGY: Reducing Breast Cancer Recurrence With Weight Loss (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=800, Active, not recruiting, Sponsor: University of California, San Diego
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Apr 2013 --> Feb 2015
- Biomarker, Trial primary completion date: Markers of Response to Intravesical Bladder Cancer Therapy (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=300, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2013 --> Feb 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- Trial primary completion date: PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy? (clinicaltrials.gov) - Dec 5, 2014
P1, N=20, Recruiting, Sponsor: University Ghent
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Oct 2012 --> Oct 2015
- |||||| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment open: Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients (clinicaltrials.gov) - Dec 5, 2014
P3, N=56, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Oct 2012 --> Oct 2015 Not yet recruiting --> Recruiting
- || rivaroxaban / Generic mfg.
Enrollment closed: Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=131, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date: Human Ovarian Autotransplantation (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=1, Completed, Sponsor: Samuel Kim, MD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=10 --> 1 | Trial primary completion date: Dec 2015 --> Mar 2014
- Clinical: An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence (clinicaltrials.gov) - Nov 23, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: University of Pittsburgh
- Trial primary completion date: Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV (clinicaltrials.gov) - Nov 20, 2014
P4, N=2018, Recruiting, Sponsor: Seoul National University Bundang Hospital
Active, not recruiting --> Completed | N=10 --> 1 | Trial primary completion date: Dec 2015 --> Mar 2014 Trial primary completion date: Dec 2015 --> Dec 2016